key: cord-1011316-ynfelmiy authors: Li, Yang; Li, Chunyang; Wang, Jian; Zhu, Chuanwu; Zhu, Li; Ji, Fang; Liu, Longgen; Xu, Tianmin; Zhang, Biao; Xue, Leyang; Yan, Xiaomin; Huang, Rui; Wu, Chao; Yan, Xuebing title: A case series of COVID‐19 patients with chronic hepatitis B virus infection date: 2020-06-19 journal: J Med Virol DOI: 10.1002/jmv.26201 sha: 30dbfac5d0b17445226b56add42cc501e4706b00 doc_id: 1011316 cord_uid: ynfelmiy Previous studies reported that coronavirus disease 2019 (COVID‐19) was likely to result in liver injury. However, few studies reported the impacts of COVID‐19 on liver function in patients with chronic liver diseases. We aimed to describe a case series of COVID‐19 patients with chronic hepatitis B virus (HBV) infection. Confirmed hospitalized COVID‐19 patients from hospitals in 10 cities of Jiangsu province, China were retrospectively included between January 18, 2020, and February 26, 2020. Demographic information, epidemiologic data, clinical features and treatment data were extracted from medical records. Seven COVID‐19 patients with chronic HBV infection were included. Six (85.7%) patients were male. The patients aged from 33 years to 49 years. Two patients had HBV‐related cirrhosis. One patients (14.3%) were positive for serum hepatitis B virus e antigen. On admission, 1 (14.3%) patients had mildly elevated ALT level (>40 U/L) and 1 (14.3%) had elevated AST level (>40 U/L). The serum albumin level and platelet counts were decreased in 2 patients with HBV‐related liver cirrhosis. Three (42.9%) patients had elevated ALT level and 2 (28.6%) patients had elevated AST level in hospitalization. However, the peak ALT and AST level during hospitalization was 51 U/L and 44 U/L, respectively. As of February 29, 2020, all patients were discharged. No patient was admitted to the intensive care units or developed liver failure during hospitalization. The abnormalities of liver function are not uncommon on COVID‐19 patients with chronic HBV infection in our case series. However, no patient developed severe liver‐related complications during hospitalization. This article is protected by copyright. All rights reserved. Since December, 2019, coronavirus disease 2019 (COVID-19) outbreak in Wuhan and spread rapidly all over the world 1 . As of June 12, 2020, 7,410,510 confirmed cases and 418,294 deaths have been reported 2 . The overall case-fatality rate was reported to be 2.3% according to a report from the Chinese center for disease control and prevention 3 . The clinical characteristics of COVID-19 patients have been described in several studies [4] [5] [6] . Although diffuse alveolar damage and acute respiratory failure are the main features of COVID-19, the impairment of other organs are demonstrated 4 This article is protected by copyright. All rights reserved. Previous studies reported that coronavirus disease 2019 was likely to induce liver injury as serum levels of alanine aminotransferase (ALT) were increased in 28% and aspartate aminotransferase (AST) were increased in 35% of patients, particularly in those who were admitted to the intensive care units (ICU) 4 10.5% of the COVID-19 patients had elevated serum total bilirubin (Tbil) 7 . However, to the best of our knowledge, few studies have reported the impacts of COVID-19 on liver function in patients with chronic liver diseases such as chronic hepatitis B (CHB). We described a case series of confirmed COVID-19 patients with chronic hepatitis B virus (HBV) infection. Three hundred and forty-two confirmed COVID- 19 9 . We randomly selected 21 COVID-19 patients without chronic HBV infection as controls by age and gender matching with chronic HBV infected patients with the ratio of 3:1. This study was approved by the institutional review boards of hospitals. Informed consent was waived due to a public health outbreak investigation. Medical records of all confirmed COVID-19 patients who were hospitalized were reviewed by more than two health care workers in each medical center. Demographic information, epidemiologic data, clinical features and treatment data were extracted from medical records. Data were recorded into a computerized database and cross-checked by different researchers to avoid errors. Throat swabs were tested for COVID-19 by real-time polymerase chain reaction according to the recommended protocol 10 . The laboratory tests included blood routine tests, liver function, coagulation function, inflammatory biomarkers, hepatitis B virus markers and HBV DNA levels. Chest computed tomography (CT) or chest radiographs were performed for each patient and the results were collected. The continuous variables were presented as medians (interquartile range (IQR)). Categorical variables were shown as the counts and percentages. The Accepted Article independent group t tests or Mann-Whitney U were used to compared continuous variables between groups. Chi-square or Fisher exact test was used for the comparisons of categorical variables. P<0.05 was considered as statistical significant. All data analysis was performed using SPSS version 22.0 software (SPSS Inc., Chicago, IL, United States). The demographic and epidemiologic characteristics of the patients were presented in Table 1 . Six (85.7%) patients were male. The patients aged from 33 years to 49 years. Four patients had known contact with confirmed COVID-19 cases and 1 patients visited Wuhan two weeks before the diagnosis. All patients had a medical history of chronic HBV infection. Two patients had HBV-related cirrhosis. No patients had chronic hepatitis C, nonalcoholic fatty liver disease or hepatocellular carcinoma. Two patients received anti-HBV treatment with entecavir for 3 and 7 years, respectively. All patients presented fever and 5 patients (71.4%) had cough at onset of illness (Table 2) . Two patients had shortness of breath and one patient had fatigue. Two patients (28.5%) showed lymphopenia on admission. Two patients had elevated serum C-reactive protein (>10 mg/L). All patients were positive for serum HBsAg on admission. Only 1 patient This article is protected by copyright. All rights reserved. The dynamic changes of ALT, AST and Tbil were presented in Figure 2 . Three (42.9%) patients had elevated ALT level and 2 (28.6%) patients had elevated AST level during hospitalization. Four patients (57.1%) had elevated serum Tbil (>17.1 μmol/l) during hospitalization. However, the peak ALT, AST and Tbil during hospitalization was 51 U/L, 44 U/L and 36.2 μmol/l, respectively. All patients had abnormalities of chest CT images. Five of the patients had ground glass opacity on chest CT images. Oxygen therapy was administered in 4 patients (Table 3) We further compared the clinical features of COVID-19 patients with and without chronic HBV infection. The results revealed that the symptoms, laboratory tests, chest CT, hospitalization days, and ICU admission rate were similar between these two groups. The levels of prothrombin time (PT) were higher in chronic HBV infected patients than non-HBV patients. However, the median levels of PT in these two groups were within normal range (Table 4 ). A case series of seven CHB patients with COVID-19 were included from 5 hospitals in Jiangsu province, China. This study showed that only one patient This article is protected by copyright. All rights reserved. had elevated ALT and one patient had elevated AST on admission. However, three (42.9%) patients developed mild elevated ALT levels and 2 (28.6%) patients had mild elevated AST levels during hospitalization. Furthermore, during hospitalization, 4 patients developed elevated Tbil. The rate of abnormalities of ALT and Tbil seems to be higher than the general population as previously reported [4] [5] [6] A Novel Coronavirus from Patients with Pneumonia in China World Health Organization. Novel Coronavirus (COVID-19) Situation This article is protected by copyright. All rights reserved Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Clinical Characteristics of Coronavirus Disease 2019 in China Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance This article is protected by copyright. All rights reserved. Accepted Article who.int/publications-detail/clinical-managementof-severe-acute-respirator y-infection-when-novelcoronavirus-(ncov)-infection-is-suspected) National Health Commission. Guidelines for the Diagnosis and Treatment of coronavirus disease 2019 (COVID-19) by the National Health Commission (Trial Version 6) World Health Organization. Laboratory diagnostics for novel coronavirus Pathological Study of the 2019 Novel Coronavirus Disease (COVID-19) Through Postmortem Core Biopsies Mod Pathol Lopinavir/ritonavir Treatment in HIV Antiretroviral-Experienced Patients: Evaluation of Risk Factors for Liver Enzyme Elevation Efficacy and Tolerability of Lopinavir/Ritonavir-And Efavirenz-Based Initial Antiretroviral Therapy in HIV-1-Infected Patients in a Tertiary Care Hospital in Beijing Role of Lopinavir/Ritonavir in the Treatment of SARS: Initial Virological and Clinical Findings Drug treatment options for the 2019-new coronavirus (2019-nCoV) Risk factors for grade 3-4 liver enzyme elevation in HIV and hepatitis C coinfected patients on combination antiretroviral therapy Pathological findings of COVID-19 associated with acute respiratory distress syndrome On the Use of Corticosteroids for 2019-nCoV Pneumonia Risk of hepatitis B surface antigen seroreversion after corticosteroid treatment in patients with previous hepatitis B virus exposure Management of patients with hepatitis B who require immunosuppressive therapy This article is protected by copyright. All rights reserved